Coverage: The Meridian legal market record (editorial).
The licence covers three named African markets and the licensee's African operating arm (Cipla Africa / Medpro Pharmaceutica) is the commercialising vehicle.
| Record ID | TX-AFR-2026-0001 |
|---|---|
| Record type | Commercial IP transaction |
| Transaction type | Exclusive licence, In-licensing |
| IP rights | not specified by source, regulatory data |
| Status | Signed |
| Qualifying date | 2026-01-20 |
| Sector | Life sciences · Pharmaceuticals – cell and gene therapy |
| African markets | South Africa, Algeria, Morocco |
| Licensed territory | South Africa, Algeria and Morocco. |
| Disclosed value | Not disclosed in the sources reviewed. |
| Evidence | Primary source, single · 1 source(s) |
| Last verified | 2026-10-25 |
Parties
- ImmunoACT (India): licensor
- Cipla (India): licensee
- Medpro (South Africa): licensee, subsidiary
Key terms
- Interest: exclusive licence to commercialise plus supply arrangement; Exclusivity: exclusive; Territorial scope: South Africa, Algeria, Morocco; Field of use: Relapsed or refractory B-cell non-Hodgkin's lymphoma and B-cell acute lymphoblastic leukaemia
Sources
- ImmunoACT partners with Cipla to launch NexCAR19 (Talicabtagene autoleucel) for Blood Cancers in Africa, ImmunoACT (Immunoadoptive Cell Therapy Pvt Ltd), 2026-01-20
Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.


